Screening of Significant Biomarkers with Poor Prognosis in Hepatocellular Carcinoma Via Bioinformatics Analysis

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2020 Aug 10

PMID 32769939

Citations 3

Authors

Quanquan Sun

Peng Liu

Bin Long

Yuan Zhu

Tongxin Liu

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) is a malignant tumor with unsatisfactory prognosis. The abnormal genes expression is significantly associated with initiation and poor prognosis of HCC. The aim of the present study was to identify molecular biomarkers related to the initiation and development of HCC via bioinformatics analysis, so as to provide a certain molecular mechanism for individualized treatment of hepatocellular carcinoma.Three datasets (GSE101685, GSE112790, and GSE121248) from the GEO database were used for the bioinformatics analysis. Differentially expressed genes (DEGs) of HCC and normal liver samples were obtained using GEO2R online tools. Gene ontology term and Kyoto Encyclopedia of Gene and Genome (KEGG) pathway analysis were conducted via the Database for Annotation, Visualization, and Integrated Discovery online bioinformatics tool. The protein-protein interaction (PPI) network was constructed by the Search Tool for the Retrieval of Interacting Genes database and hub genes were visualized by Cytoscape. Survival analysis and RNA sequencing expression were conducted by UALCAN and Gene Expression Profiling Interactive Analysis.A total of 115 shared DEGs were identified, including 30 upregulated genes and 85 downregulated genes in HCC samples. P53 signaling pathway and cell cycle were the major enriched pathways for the upregulated DEGs whereas metabolism-related pathways were the major enriched pathways for the downregulated DEGs. The PPI network was established with 105 nodes and 249 edges and 3 significant modules were identified via molecular complex detection. Additionally, 17 candidate genes from these 3 modules were significantly correlated with HCC patient survival and 15 of 17 genes exhibited high expression level in HCC samples. Moreover, 4 hub genes (CCNB1, CDK1, RRM2, BUB1B) were identified for further reanalysis of KEGG pathway, and enriched in 2 pathways, the P53 signaling pathway and cell cycle pathway.Overexpression of CCNB1, CDK1, RRM2, and BUB1B in HCC samples was correlated with poor survival in HCC patients, which could be potential therapeutic targets for HCC.

Citing Articles

Computed tomography radiomics signature via machine learning predicts and overall survival in hepatocellular carcinoma.

Li Q, Long X, Lin Y, Liang R, Li Y, Ge L J Gastrointest Oncol. 2023; 14(3):1462-1477.

PMID: 37435222 PMC: 10331770. DOI: 10.21037/jgo-23-460.

Comprehensive Analysis of Gene Expression Changes and Validation in Hepatocellular Carcinoma.

Zhang H, Liu R, Sun L, Guo W, Ji X, Hu X Onco Targets Ther. 2021; 14:1021-1031.

PMID: 33623390 PMC: 7894825. DOI: 10.2147/OTT.S294500.

Identification of a prognostic gene signature of colon cancer using integrated bioinformatics analysis.

Fang Z, Xu S, Xie Y, Yan W World J Surg Oncol. 2021; 19(1):13.

PMID: 33441161 PMC: 7807455. DOI: 10.1186/s12957-020-02116-y.

References

Mukherjee A, Joseph C, Craze M, Chrysanthou E, Ellis I . The role of BUB and CDC proteins in low-grade breast cancers. Lancet. 2015; 385 Suppl 1:S72. DOI: 10.1016/S0140-6736(15)60387-7. View

Shao J, Liu X, Zhu L, Yen Y . Targeting ribonucleotide reductase for cancer therapy. Expert Opin Ther Targets. 2013; 17(12):1423-37. DOI: 10.1517/14728222.2013.840293. View

Chen H, Lee J, Kljavin N, Haley B, Daemen A, Johnson L . Requirement for BUB1B/BUBR1 in tumor progression of lung adenocarcinoma. Genes Cancer. 2015; 6(3-4):106-18. PMC: 4426948. DOI: 10.18632/genesandcancer.53. View

Zhang G, Lopez Mendez B, Sedgwick G, Nilsson J . Two functionally distinct kinetochore pools of BubR1 ensure accurate chromosome segregation. Nat Commun. 2016; 7:12256. PMC: 4963475. DOI: 10.1038/ncomms12256. View

Cao H, Xu Z, Wang J, Cigliano A, Pilo M, Ribback S . Functional role of SGK3 in PI3K/Pten driven liver tumor development. BMC Cancer. 2019; 19(1):343. PMC: 6458829. DOI: 10.1186/s12885-019-5551-2. View

Zhang H, Zhang X, Li X, Meng W, Bai Z, Rui S . Effect of CCNB1 silencing on cell cycle, senescence, and apoptosis through the p53 signaling pathway in pancreatic cancer. J Cell Physiol. 2018; 234(1):619-631. DOI: 10.1002/jcp.26816. View

Fu X, Chen G, Cai Z, Wang C, Liu Z, Lin Z . Overexpression of BUB1B contributes to progression of prostate cancer and predicts poor outcome in patients with prostate cancer. Onco Targets Ther. 2016; 9:2211-20. PMC: 4844448. DOI: 10.2147/OTT.S101994. View

Liu Y, Zhu Y, Mao C, Dou S, Shen S, Tan Z . Triple negative breast cancer therapy with CDK1 siRNA delivered by cationic lipid assisted PEG-PLA nanoparticles. J Control Release. 2014; 192:114-21. DOI: 10.1016/j.jconrel.2014.07.001. View

Zhang Y, Huang W, Ran Y, Xiong Y, Zhong Z, Fan X . miR-582-5p inhibits proliferation of hepatocellular carcinoma by targeting CDK1 and AKT3. Tumour Biol. 2015; 36(11):8309-16. DOI: 10.1007/s13277-015-3582-0. View

10.

Liu X, Xu Z, Hou C, Wang M, Chen X, Lin Q . Inhibition of hepatitis B virus replication by targeting ribonucleotide reductase M2 protein. Biochem Pharmacol. 2016; 103:118-28. DOI: 10.1016/j.bcp.2016.01.003. View

11.

Liu J, Zhang C, Hu W, Feng Z . Tumor suppressor p53 and its mutants in cancer metabolism. Cancer Lett. 2013; 356(2 Pt A):197-203. PMC: 4069248. DOI: 10.1016/j.canlet.2013.12.025. View

12.

Kern S . Why your new cancer biomarker may never work: recurrent patterns and remarkable diversity in biomarker failures. Cancer Res. 2012; 72(23):6097-101. PMC: 3513583. DOI: 10.1158/0008-5472.CAN-12-3232. View

13.

Malumbres M, Barbacid M . Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009; 9(3):153-66. DOI: 10.1038/nrc2602. View

14.

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

15.

Lee B, Ha S, Song D, Lee H, Cho S, Park C . High expression of ribonucleotide reductase subunit M2 correlates with poor prognosis of hepatocellular carcinoma. Gut Liver. 2014; 8(6):662-8. PMC: 4215454. DOI: 10.5009/gnl13392. View

16.

DiStefano J, Davis B . Diagnostic and Prognostic Potential of AKR1B10 in Human Hepatocellular Carcinoma. Cancers (Basel). 2019; 11(4). PMC: 6521254. DOI: 10.3390/cancers11040486. View

17.

Ricardo-Lax I, Ramanan V, Michailidis E, Shamia T, Reuven N, Rice C . Hepatitis B virus induces RNR-R2 expression via DNA damage response activation. J Hepatol. 2015; 63(4):789-96. DOI: 10.1016/j.jhep.2015.05.017. View

18.

Ma Q, Liu Y, Shang L, Yu J, Qu Q . The FOXM1/BUB1B signaling pathway is essential for the tumorigenicity and radioresistance of glioblastoma. Oncol Rep. 2017; 38(6):3367-3375. PMC: 5783581. DOI: 10.3892/or.2017.6032. View

19.

Ersvaer E, Kildal W, Vlatkovic L, Cyll K, Pradhan M, Kleppe A . Prognostic value of mitotic checkpoint protein BUB3, cyclin B1, and pituitary tumor-transforming 1 expression in prostate cancer. Mod Pathol. 2019; 33(5):905-915. PMC: 7190565. DOI: 10.1038/s41379-019-0418-2. View

20.

Ravindran Menon D, Luo Y, Arcaroli J, Liu S, KrishnanKutty L, Osborne D . CDK1 Interacts with Sox2 and Promotes Tumor Initiation in Human Melanoma. Cancer Res. 2018; 78(23):6561-6574. PMC: 6279496. DOI: 10.1158/0008-5472.CAN-18-0330. View